Get startedLog in
    Picture of AstraZeneca logo

    AZN — AstraZeneca News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareConservativeLarge CapHigh Flyer
    All News

    Brief: Astrazeneca Says Truqap Combination Approved In US For A Type Of Prostate Cancer

    Picture of AstraZeneca logoAstraZeneca
    12/06/2026 19:03
    BRIEF-Astrazeneca Says Truqap Combination Approved In US For A Type Of Prostate Cancer
    June 12 (Reuters) - AstraZeneca PLC AZN.L:
    • ASTRAZENECA: TRUQAP COMBINATION APPROVED IN US AS FIRST AND ONLY TARGETED TREATMENT FOR PTEN-DEFICIENT METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    • ASTRAZENECA: FDA ALSO APPROVED COMPANION DIAGNOSTIC TEST TO DETECT PTEN DEFICIENCY IN TUMOURS OF PATIENTS WITH PROSTATE ADENOCARCINOMA
    Further company coverage: AZN.L

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on AstraZeneca

    See all news